搜索优化
Rewards
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
2 天
诺和诺德下一代减肥药monlunabant试验减重效果不佳 股价大跌5%
丹麦制药公司诺和诺德(Novo Nordisk A/S)周五报告称,该公司下一代减肥药之一monlunabant在较高剂量时减重效果有限,而且有一定副作用,导致该公司股价周五下跌。
2 天
诺和诺德股价重挫近6%!减肥口服药试验结果喜忧参半
消息面上,诺和诺德在官网发布了药物“monlunabant”2a期临床试验的主要结果。整体来看, 与安慰剂相比,该药物具有显著统计学意义的体重减轻。但在较高剂量的组别中,体重额外减轻的效果有限。
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
今日热点
Alabama mass shooting
Daylight saving time
Visits US ammunition plant
Ga. suspect's mom indicted
San Francisco homelessness
Released after guilty plea
Economic speech this week
California plastic bag ban
Biden hosts 'Quad' summit
No. 1 at box office again
Pandas leaving for China
TN abortion law blocked
Drug price challenge revived
CA firefighter held for arson
Donlon's homes searched
Former WA governor dies
Boeing defense chief exits
ISR raids Al Jazeera office
CA bill to protect kids online
J&J unit files for bankruptcy
Suns broadcaster dies
SC 1st execution in 13 years
Robinson loses key staff
Iran coal mine blast
Sesame Place suit verdict
Hezbollah rockets hit Israel
Free COVID-19 tests
Dolphins legend Morris dies
Trump to campaign in MI
No govt. shutdown for now
PM Modi visits US
反馈